Durval Campos Costa, MD, MSc, PhD, FRCR is the Director of the Nuclear Medicine-Radiopharamacology Unit at Champalimaud Clinical Centre, Champalimaud Foundation. In addition to his work at the clinic, he also holds or held several national and international positions such as (the most recent) President of the Executive Committee of Section and European Board of the European Union of Medical Specialists (mandate 2012 – 2015). Durval has more than 30 years’ experience in all diagnostic and therapeutic (outpatient and inpatient) activities in Nuclear Medicine. He has pioneered the introduction of new diagnostic radiopharmaceutical methodology in Psychiatry, Neurology and Cardiology, from 1985 to present, all with international recognition. These include markers of cerebral blood flow and dopamine metabolism within the Central Nervous System that he developed from basic research to clinical applications. In addition, he pioneered the introduction of Positron Emission Tomography (PET) in Portugal in 2002. Furthermore, he was also at the forefront of the introduction of Cyclotron production of radiopharmaceuticals in Portugal (1st cyclotron installed in the district of Porto in 2005 starting production in 2009). Durval’s research interests include the development of new radiopharmaceuticals for clinical application, as well as new protocols for the investigation of disease physiopathology and its progression. He also extensively studies Functional Neuroimaging from basic research to clinical development of several radiolabeled markers. He also continues to implement basic research and clinical development of Positron Emission Tomography (PET) and PET-CT in Oncology, Neurology and Cardiology.